Beyond their glucose-lowering effects, SGLT2 inhibitors have demonstrated cardiovascular benefits, including reductions in hospitalization of T2DM patients with cardiovascular events and heart failure. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.